Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Swing Traders » BIPH

 - UBBFriend: Email this page to someone!    
Author Topic: BIPH
Original_Cashmaker
Member


Member Rated:
4
Icon 1 posted      Profile for Original_Cashmaker     Send New Private Message       Edit/Delete Post   Reply With Quote 
Good entry point, poised for a bounce:

ROCHESTER, N.Y.--(BUSINESS WIRE)--May 6, 2005-- Biophan Technologies, Inc. (OTCBB:BIPH - News), a developer of next-generation medical technology, has announced the filing of an SEC Form 8K/A report detailing its acquisition of technology innovators aMRIs and MR:Comp, two German companies conducting research and development in advanced technologies involving Magnetic Resonance Imaging (MRI). Under the terms of the transaction, disclosed in the SEC Form 8K/A, Biophan acquired 51% of aMRIs GmbH, while aMRIs acquired 58.4% ownership of MR Comp GmbH.

Biophan’s acquisition of the companies brought a range of patents, technology and expertise that the Company expects will produce commercial solutions and products in a number of biomedical fields that may benefit from improved MRI safety and compatibility. aMRIs, renamed Biophan Europe after the acquisition, now serves as Biophan’s principal marketing and research presence in Europe .

“Although these acquisitions of aMRIs and MR Comp are still quite recent, they have already started to yield significant benefits for Biophan,” said Michael Weiner, Biophan CEO. “For example, Biophan Europe has recently announced the start of important animal trials of a pioneering MRI-visible vena cava filter, which are used to prevent serious lung embolisms.”

aMRIs develops active MRI systems for enhanced visualization and therapeutic applications. Among its technologies, in addition to the Vena Cava filter, are advanced MRI-compatible and active endovascular stents, filters, valves, occluders, and catheters. One of the important technologies that came to Biophan as a result of the acquisition is aMRIs’ resonant circuit technology, which enables the production of vascular stents and other medical devices whose interior can be accurately imaged by MRI systems. The interiors of current generations of stents cannot be well-imaged by MRI, requiring physicians to use more invasive methods to determine stent-related health, such as the presence of restenosis, or post-implantation blockage.

Biophan recently made available MRI images demonstrating the ability of its proprietary resonant frequency circuitry to enable the creation of clear and useful MRI images of Vena Cava filters. A Biophan news release about the technology can be read at http://www.biophan.com/pr/042605VenaCava.html. Samples of the Company’s MRI images of Vena Cava filters can be viewed as a PowerPoint presentation by visiting http://www.trilogy-capital.com/tcp/biophan/presentationhtml. Please click on the “Multimedia Content” option on the Biophan information page to view the presentation.

MR:Comp tests medical devices for MRI safety and compatibility, and provides comprehensive consulting services for product improvements, new product development and personnel training. As a developer of innovative biomedical products focused on MRI functionality and safety, Biophan expects to benefit from improved access to MR:Comp’s scientific expertise and equipment.

About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

--------------------
Got stars?

Posts: 833 | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
dodo
Member


Rate Member
Icon 1 posted      Profile for dodo     Send New Private Message       Edit/Delete Post   Reply With Quote 
I've owned this one a few times. It was over $3 within the past few months.
Posts: 104 | Registered: May 2005  |  IP: Logged | Report this post to a Moderator
Original_Cashmaker
Member


Member Rated:
4
Icon 1 posted      Profile for Original_Cashmaker     Send New Private Message       Edit/Delete Post   Reply With Quote 
up 10% today not bad

--------------------
Got stars?

Posts: 833 | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share